Difference between revisions of "Part:BBa K4165156"

Line 9: Line 9:
 
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).
 
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).
  
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165156 SequenceAndFeatures</partinfo>
 
  
 
===Dry Lab===
 
===Dry Lab===
Line 33: Line 30:
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
</html>
 
</html>
 +
 +
<!-- -->
 +
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 +
<partinfo>BBa_K4165156 SequenceAndFeatures</partinfo>
 +
  
  

Revision as of 13:54, 6 October 2022


MM2 Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).


Dry Lab

Modeling

MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta.


                            Figure 1.: Predicted 3D structure of Synthetic peptide MM2.


Table 1: Quality assessment parameters of MM2 model.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


References

1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).